US 6719996

I'll run targeted searches for this specific patent number, including any 2026 CAFC docket activity.

No CAFC 2026 activity surfaced in those hits — the "6719996" matches were unrelated docket/document numbers and an Australian application number. Let me run one more targeted check for litigation.

Summary — U.S. Patent No. 6,719,996 B2

Important caveat up front: My searches of public sources (Google Patents, PubChem, Justia, EPO family data, RPX/CourtListener litigation documents) turned up no CAFC 2026 docket, no IPR, and no district-court infringement action naming U.S. Patent 6,719,996. Searches for "6719996" in CAFC/2026 materials returned unrelated coincidental numbers (e.g., a docket-entry number in Glazer Capital Mgmt. v. Magistri, 9th Cir. 2008; an Australian application number AU 6719996 A in a WO 9706393 family annex). I cannot confirm any 2026 Federal Circuit activity for this patent, and I will not invent one. The facts below are grounded in the authoritative patent text you supplied plus corroborating public records.

Bibliographic data (per Google Patents / PubChem)

Public records (e.g., EP 2,722,045 B1 background text) confirm this patent is one of three Hoffmann-La Roche filings covering the NK-1 antagonist netupitant and its formulations: U.S. 6,297,375; 6,719,996; and 6,593,472.

Abstract (verbatim)

"A pharmaceutical composition for oral administration of an active compound having a bioavailability of 20% or less. The composition comprises, based on its total weight, from 0.01% to about 15% (w/w) of said active compound molecularly dissolved in the composition, from 30 to 80% (w/w) of an edible lipid matrix and from 1 to 20% (w/w) of an edible emulsifier, the ratio between the dose weight of the active compound and its solubility in the composition being equal to or greater than 0.6 ml. The high percentage of fat (30-80%) enables a considerable increase the amount of the drug that is molecularly dispersed in the dosage form, thus allowing a significant reduction in the number of unit doses that must be taken daily-by patients."

Plain-language overview of the independent claims

Only two claims are independent. Every other claim (2–26) depends from claim 1.

Independent claim 1 — the composition. A chewable oral pharmaceutical composition (a "Self-Emulsifying Lipid Matrix," SELM) for a drug whose bioavailability is 20% or less, containing, by total weight:

• 0.01%–15% w/w of the active compound, molecularly dissolved (not suspended/crystalline) in the composition;
• 30%–80% w/w of an edible lipid matrix (e.g., cocoa butter, vegetable triglycerides);
• 1%–20% w/w of an edible emulsifier (e.g., lecithins, polyglycolized triglycerides);
• where the ratio of the dose weight (mg) of drug to its solubility (mg/mL) in the composition is ≥ 0.6 mL — i.e., enough lipid volume exists to hold the full dose in true solution;
• and the composition must be a "chewable unit dosage form resembling a piece of chocolate."

That final negative-limitation-style element is the notable narrowing versus the published application (US 2002/0114837 A1), whose claim 1 lacked any dosage-form/appearance requirement and instead claimed an oral composition alone. Its addition at grant aligns with the examiner's cited art — particularly US 6,375,982 B1 (Capricorn Pharma, "Rapid-melt semi-solid compositions") and WO 97/36577 (Pharmos, solid lipid compositions of lipophilic compounds) — indicating the "chewable unit dose resembling chocolate" element was the point of novelty that secured allowance.

Independent claim 27 — the process. A method of making that chewable, chocolate-like composition comprising: (i) selecting an active compound with ≤20% bioavailability, an edible lipid matrix, and an edible emulsifier; and (ii) mixing 0.01%–15% w/w drug, 30%–80% w/w lipid matrix, and 1%–20% w/w emulsifier such that the dose-weight/solubility ratio is ≥ 0.6 mL.

Dependent claim highlights (claims 2–26)

• Claim 2: lipid matrix 50%–75% w/w. Claims 3–4: emulsifier 1%–10%, preferably 2%–8% w/w.
• Claim 5: lipid matrix selected from natural/semi-synthetic vegetable triglycerides and hydrogenated vegetable glycerides. Claim 6: cocoa butter.
• Claims 7–8: emulsifier = lecithins or polyglycolized triglycerides; preferably soya lecithin. Claim 9: optional sweeteners/flavors.
• Claims 10–12: the dose/solubility ratio ≥1.2 mL, preferably 1.2–10 mL, most preferably 3–7 mL.
• Claims 13–15: drug classes (sulfonamides, dihydropyridines, isoquinoline derivatives, 4-phenylpyridin derivatives, phenylamino-[5-ethoxy-2-fluoro-4-(2-hydroxy-ethoxy)-phenyl] derivatives), narrowed to 4-phenylpyridin derivatives, then to three named compounds — including netupitant (2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide) and the compound of EP-A-1035115.
• Claims 16–26: mirror the claim 2–12 limitations, re-drafted as dependent on the specific-compound claim 15.

Technical/metric substance worth noting

The Examples (1–4 are SELM; Example 5 is a comparative SEDDS of Tween 80/Miglyol 812) report beagle-dog bioavailabilities up to 68% for the SELM chewable tablets at 70 mg drug load per 5 g unit dose, versus 13–27% for the comparative SEDDS and 0.6–7% for conventional crystalline-drug capsules (Tables 1–2). This is the factual basis for the patent's stated advance: high lipid load permits a large single-unit dose volume, reducing pill burden.

Uncertainty / limits on what I could verify

• No CAFC 2026 (or any) appellate docket for 6,719,996 was found. I cannot state that none exists; I can only state that public search results did not surface one, and that the coincidental "6719996" hits were docket/document numbers, not this patent.
• No litigation or IPR involving 6,719,996 surfaced; the Helsinn/Roche Hatch-Waxman suits I found (Helsinn Healthcare S.A. v. Teva, D.N.J. 11-cv-03962, and related D. Del. actions) asserted different patents (7,947,724; 7,947,725; 7,960,424; 8,598,218; 8,598,219; 8,518,981), not 6,719,996.
• Discrepancy flag (not auto-corrected): The specification repeatedly writes "SEEDS" for "SEDDS" (and defines "SELM"). Per your rules I have preserved the patent's literal text and not silently normalized it.
• The Google Patents legal-status line ("Expired – Lifetime, expires 2022-02-26") reflects an adjusted expiration derived from the 2001-12-10 filing plus patent-term adjustment; maintenance fees were paid at years 4, 8, and 12 (2007, 2011, 2015) per the record. I flag the status as an assumption of the source, not a legal conclusion.

Primary sources: https://patents.google.com/patent/US6719996/en ; https://pubchem.ncbi.nlm.nih.gov/patent/US-6719996-B2 ; https://patents.justia.com/patent/20020114837 ; EPO family/litigation references at http://data.epo.org and https://www.bipc.com/assets/PDFs/Insights/Opinion-Intellectual_Property-Helsinn_Healthcare_v_Teva_Pharmaceuticals_USA-20160303.pdf

I'll search for litigation records involving US patent 6719996.

Let me search more targeted sources for litigation records.

Bottom line

I found no litigation (district court, ITC, CAFC, PTAB, or foreign) involving U.S. Patent No. 6,719,996. There is consequently no plaintiff/defendant/jurisdiction/case-number/outcome table to populate — the correct answer is "none known."

Because you asked for a case list, the empty result is stated explicitly below, together with what I searched and the false positives I had to discard.

1. Patent identity (confirmed, interpreted literally)

Source: https://patents.google.com/patent/US6719996/en (authoritative text supplied); PubChem summary at https://pubchem.ncbi.nlm.nih.gov/patent/US-6719996-B2

2. Litigation found

None. No case was identified in which US 6,719,996 was asserted, challenged, or otherwise placed at issue.

Notably, the patent's own record shows no post-grant proceedings and no transfer to a monetization entity:

• No IPR/PGR/CBM or reexamination appears in the Google Patents prosecution/legal-events history for US 10/015,925 (only routine fee payments in 2007, 2011, 2015).
• No reassignment beyond the original 2001/2002 Roche intra-group assignments and the 2002 grant record.
• The only litigation-adjacent activity in the family is third-party citation of US 6,719,996 in later patents (e.g., the Helsinn netupitant/fosnetupitant family — US 8,426,450; WO 2011/061622; US 8,954,969; etc.). Being cited by those patents is not litigation, and no case was found in which the '996 patent itself was asserted.

3. Searches performed and false positives excluded

I searched for the exact number and variants ("US 6719996", "6,719,996", "6719996 patent lawsuit/infringement", Roche/Helsinn ± SELM/netupitant) across patent and litigation-oriented sources. The following hits used the same digit string but are not US 6,719,996 and were discarded per your instruction not to auto-correct or conflate identifiers:

1. "DktEntry: 6719996" in Glazer Capital Management v. Magistri, No. 06-16899 (9th Cir. 2008) — a PACER docket-entry number in a securities-fraud class action, unrelated to any patent.
2. AU 6719996 A — an Australian application, "Method for bulking tuftstring carpets" (Milliken/Ontera; abandoned). Different jurisdiction, different subject matter, different number series.
3. A "6719996" row in a sequence-listing table of EP 2 529 032 B1 — a SEQ ID region coordinate, not a patent citation.
4. "AU 6719996 A" appearing in the family annex of WO 97/06393 — the same Australian carpet application again.
5. General Roche litigation hits (Hoffmann-La Roche v. Lemmon, Apotex v. Syntex, Canadian Patent 1,204,671, the Enbrel/Sandoz matter) all involve different patents and were excluded.

None of these is evidence of litigation over US 6,719,996.

4. Caveats on confidence

• I could not directly query PACER, Docket Navigator, or the Unified Patents litigation portal in this session; my results come from open-web indexing of those and similar sources. A zero-result web search is weaker evidence of absence than a direct docket search.
• It is possible but unlikely that an unindexed, sealed, or quickly-settled/voluntarily-dismissed suit exists. Given the patent's expiration on 2022-02-26, any new assertion is now time-barred, and its 2004–2022 enforceability window shows no record of assertion by Roche.
• I do not have high confidence in any specific negative claim about foreign proceedings; I found no reported foreign action involving this patent or its family members (EP 1,349,541; JP 4116436; KR 100602299; CN 1263446; CA 2,431,397).

Conclusion: On the available record, US 6,719,996 has no known litigation history.

I'll verify the canonical "no proceedings" signal against public dockets before writing.

No PTAB hits so far. Let me run a few more targeted checks (netupitant/NK-1 art, Unified Patents, and PTAB E2E-style queries).

Let me do two final confirmatory checks — one on PTAB E2E/decisions and one on litigation assertion history (which explains the absence of IPRs).

PTAB / AIA Trial Proceedings — US 6,719,996 B2

Proceedings overview

There are zero AIA trial proceedings on file against US 6,719,996. The USPTO Open Data Portal block supplied with this prompt returns no IPR, PGR, or CBM for the patent, and my independent searches of PTAB filings/decisions and secondary PTAB trackers surfaced no petition naming the '996 patent as the challenged patent — so the breakdown is 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denials. The bottom line for a defendant is unusual and double-edged: the patent was never battle-tested at the PTAB, so all 27 claims stand un-narrowed and there is no FWD, no claim-cancellation, and no § 315(e) estoppel to leverage — but the patent itself expired on 2022-02-26 (adjusted expiration, "Expired - Lifetime"), which caps your real-world exposure to the pre-expiration damages window regardless of claim validity.

No proceedings to report — but two false-positive traps to be aware of

Because the per-proceeding template assumes at least one filing, here is what diligence actually found, including the two things that look like PTAB activity on this patent family but are not.

False positive #1 — Azurity/Helsinn netupitant IPRs. There is a live cluster of IPRs against Helsinn Healthcare patents covering netupitant/palonosetron (e.g., US 9,186,357, US 10,828,297, US 11,312,698), brought by Azurity Pharmaceuticals (a representative petition is IPR2025-00947; see the published petition at https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf). These are different patents owned by a different party. US 6,719,996 does not appear as the challenged patent in any of them.

False positive #2 — the '996 patent as cited prior art, not as a target. The '996 patent is listed in the "References Cited" section on the face of the Helsinn patents (e.g., US 10,828,297 and US 11,312,698, as shown in the complaint exhibit at https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.1.1.pdf — "6,719,996 B2 4/2004 Kuentz et al."). A prior-art citation on the face of a later patent is not a PTAB proceeding against the '996 patent, and it creates no estoppel against anyone. Do not let opposing counsel or your own docketing vendor conflate the two.

No petition located. Repeated searches combining the patent number with "IPR," "PTAB," "inter partes review," "Unified Patents," "Kuentz," "Roethlisberger," and the NK-1/netupitant art returned only the patent's own family page (https://patents.google.com/patent/[US6719996B2](/patent/US6719996B2)/en), PubChem's patent record (https://pubchem.ncbi.nlm.nih.gov/patent/US-6719996-B2), and unrelated documents. I found no Unified Patents or defensive-aggregator filing, and no district-court assertion of the '996 patent in the sources I could reach. I did not exhaustively review every USPTO PTAB E2E docket entry or every district-court docket; if you need a belt-and-suspenders confirmation, run the patent number through PTAB E2E (https://ptacts.uspto.gov/ptacts/) and the IPR/PGR tabs of Patent Center before you rely on this in a filing.

What the patent actually is (context for the zero-proceeding result)

• Patent: US 6,719,996 B2, "Galenic composition for low bioavailability medicaments"
• Inventors: Martin Kuentz; Dieter Roethlisberger
• Assignee of record: Hoffmann-La Roche Inc. (original); F. Hoffmann-La Roche AG (assignment recorded 2002-02-19)
• Application: 10/015,925 — Filed: 2001-12-10 — Priority: 2000-12-14 (EP 00127414.1) — Granted: 2004-04-13
• Status: Expired – Lifetime; adjusted expiration 2022-02-26
• Claim set: 27 claims. Independent claim 1 (composition, closed by "which comprises a chewable unit dosage form resembling a piece of chocolate") and independent claim 27 (process). Claims 2–26 depend from claim 1; the claim-15 sub-genus and its dependents (16–26) are directed to the three named 4-phenylpyridin / NK-1 antagonist compounds.
• Art cited on the face of the patent (relevant if you ever need to rebuild a § 103 theory): WO 1997/036577 A1 (Pharmos, "Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability"), EP 1035115 A1 (Roche, "4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists"), US 6,375,982 B1 (Capricorn Pharma, "Rapid-melt semi-solid compositions"), plus non-patent literature Aungst et al., Int'l J. Pharmaceutics 156(1):79–88 (1997) and Serajuddin et al., J. Pharm. Sci. 88(10):1058–1066 (1999).
• Parallel national filings: WO 2002/047663 A1; EP 1349541 B1; JP 4116436 B2; KR 100602299 B1; CN 1263446 C; CA 2431397 C.

Strategic summary

Claim status: everything is UNTESTED. No claim of US 6,719,996 has been canceled, confirmed, or even construed by the PTAB, because no petition was ever filed. Independent claim 1 and independent claim 27 — including the distinctive "chewable unit dosage form resembling a piece of chocolate" limitation — remain in force as issued. The most likely practical reason for the PTAB vacuum is simply that the patent expired on 2022-02-26; by the time chewable/chocolate-matrix lipid-formulation art became a crowded commercial space (the 3D-printed and chocolate-based pediatric dosage-form literature, e.g., Karavasili et al. 2020, is cited as similar art on the Google Patents family page), the '996 patent's enforceable term was gone or nearly gone. Petitions are not filed against patents nobody can be sued on.

Estoppel landscape: empty. Because there is no IPR or PGR, no petitioner is subject to § 315(e)(2) estoppel and no prior art is off the table for anyone. A defendant today is free to raise any § 102/§ 103/§ 112 ground, in any forum, without estoppel risk — but note the reverse: you also get no benefit from anyone else's work product (no FWD findings of unpatentability to adopt, no institution decision reasoning to crib). You would be litigating validity from scratch, and there is no PTAB record to lean on.

Pattern signals: none. No petitioner filed multiple IPRs against this patent; the patent owner has never pursued a PTAB appeal of anything; and no defensive aggregator (Unified Patents, RPX, etc.) appears in the chain. The only adjacent activity — the Azurity v. Helsinn IPR cluster over the netupitant/palonosetron patents — involves a different patent owner and different patents, and the '996 patent shows up there only as a citation in Helsinn's own "References Cited" lists. On the current record, this is a dormant, expired formulation patent, not a hardened or repeatedly-attacked one.

Recommended next steps

• Lead with expiry, not validity. The single most useful fact for a defendant is the 2022-02-26 adjusted expiration. Any damages theory is confined to acts of infringement occurring no more than six years before the complaint under 35 U.S.C. § 286, and in practice to the period before expiry. Before you spend money on an invalidity case, confirm the expiration date and the maintenance-fee history on Patent Center (fee payments are recorded at years 4, 8, and 12 in the legal-events log, 2007-09-14, 2011-09-23, and 2015-09-24).
• Do not assume PTAB activity. If your docketing vendor flags "netupitant IPR" next to this patent, verify the challenged patent number. The Azurity petitions target Helsinn patents (US 9,186,357 and its siblings) — see https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf — and the '996 patent is merely prior art cited against those claims. Misreading this could produce a materially wrong invalidity/estoppel posture.
• If you are facing a demand letter citing US 6,719,996: (i) demand the accused product, the asserted claims, and the accused acts' dates, and check them against 2022-02-26; (ii) note there is no IPR, no FWD, no reexamination certificate, and no district-court validity holding on this patent — so any assertion of "hardened" or "PTAB-confirmed" claims is unsupported; and (iii) if the patent is still being asserted notwithstanding expiry, consider whether the claim chart maps to claim 1's "chewable unit dosage form resembling a piece of chocolate" limitation, which no tribunal has ever construed.
• If, contrary to the structured ODP block, a petition has recently been filed, the milestones are statutory: a Patent Owner Preliminary Response is due within 3 months of notice, the Director's institution decision is due within 6 months of the petition's filing date, and any instituted trial carries a 1-year FWD deadline from institution (extendable only for good cause under § 316(a)(11)). Nothing in the record I could reach indicates such a filing exists.

Caveats and confidence level. High confidence that the ODP structured block reports no AIA trial proceedings for US 6,719,996, and that no FWD, settlement, or CAFC appeal exists for this patent. I did not surface any IPR/PGR/CBM number naming this patent, and the task instructions prohibit inventing proceeding numbers, so none is reported. I could not fully rule out (a) an ex parte reexamination (not an AIA trial, and outside the ODP PTAB block), (b) a district-court validity challenge never reduced to a published opinion, or (c) an unindexed, very recent filing. If any of those matters to your analysis, confirm directly on PTAB E2E (https://ptacts.uspto.gov/ptacts/) and the patent's PTAB/reexam tabs in Patent Center before relying on this memo.

US 6,719,996 B2 — Ownership & Assignment Analysis

Note on sources. Google Patents' legal-events record for this patent (which mirrors the USPTO assignment data) is the authoritative record I could actually reach. The USPTO Assignment Center UI at https://assignmentcenter.uspto.gov/ was not directly queryable during this analysis, so the reel/frame entries below are taken from the recorded-assignment entries reproduced on the patent's Google Patents page. Fields the Assignment Center exposes but Google Patents does not reproduce — notably the correspondent of record for each recording — could not be verified and are flagged as unknown rather than guessed.

Inventors

Both inventors are named on the face of the patent (PubChem record: "KUENTZ MARTIN (CH); ROETHLISBERGER DIETER (CH)"). Employer is determinable directly from the assignment instruments: on 2001-11-21 both inventors executed an assignment of their rights to F. Hoffmann-La Roche AG (reel 012639/0267), i.e. they were Roche R&D employees at the time of filing (2001-12-10).

Unusual-pattern check: No. The instruments show the standard Roche corporate pattern — inventor → Swiss parent → US operating subsidiary — executed before the filing date. There is no recorded evidence of either inventor departing, and no post-issuance inventor-side assignments exist. I cannot substantiate any "inventors left within 12 months" signal; do not read one in.

Original assignee

Hoffmann-La Roche Inc. (the US subsidiary of F. Hoffmann-La Roche AG; "current assignee" per Google Patents = Hoffmann La Roche Inc., Nutley, New Jersey).

• Business: Roche is a large operating pharmaceutical/diagnostics company. The US entity was the group's US pharma operating arm until Roche consolidated US pharma into Genentech (South San Francisco) and ran down the Nutley site (~2013).
• Product embodying the claims? No evidence found. The claims are directed to a chewable unit dosage form resembling a piece of chocolate — a Self-Emulsifying Lipid Matrix ("SELM") delivery form. No Roche-marketed product of that form was identified. The drug substance used throughout the examples (the 4-phenylpyridin derivative, later known as netupitant) did reach market — but as Akynzeo (netupitant/palonosetron), marketed by Helsinn Healthcare S.A., which licensed the Roche NK-1 chemistry. Akynzeo is a conventional oral capsule/tablet, not the SELM chewable form claimed here. So the claimed subject matter was never commercialized by the assignee.
• Current status: Roche Holding AG is operating. This particular patent expired — lifetime on 2022-02-26 (adjusted expiration) and the family is now public domain.

Cross-checks confirming Roche remains the owner of record: (i) no assignment event appears after the two 2002 recordings in the patent's legal events; (ii) the patent is cited as a Roche document in later third-party filings (e.g. Helsinn's netupitant family, EP 2 759 298 A1 cites "US 6719996 B … KUENTZ MARTIN [CH]") and appears in a Helsinn v. Gland Pharma (D.N.J. 3:22-cv-04635) exhibit table (CourtListener docket 63601016) — as a cited document, not as an asserted patent.

Assignment timeline

Two recorded entries, both recorded on the same day, on the same reel (012639), covering pre-filing transfers within one corporate family. These are the only recorded assignments.

• 2001-11-21 (executed) / recorded 2002-02-19 — Reel 012639/0267

  • Conveyance: Assignment
  • Assignor: Kuentz, Martin; Roethlisberger, Dieter (inventors)
  • Assignee: F. Hoffmann-La Roche AG, Switzerland
  • Correspondent: Not retrievable from the sources reached (Google Patents does not reproduce the correspondent field). No finding can be made on the repeat-correspondent signal without this field.
  • Context: Standard employee invention assignment to the Swiss parent, executed ~3 weeks before the 2001-12-10 US filing.

• 2001-11-22 (executed) / recorded 2002-02-19 — Reel 012639/0256

  • Conveyance: Assignment
  • Assignor: F. Hoffmann-La Roche AG
  • Assignee: Hoffmann-La Roche Inc. (New Jersey)
  • Correspondent: Not retrievable (same reel 012639 as the entry above; consistent with a single recording agent handling both instruments, but not verifiable here).
  • Context: Intra-group transfer to the US operating subsidiary, one day after the inventors' assignment; standard parent→US-subsidiary holding structure.

• No further recorded assignments. Nothing after 2002-02-19. No security interests, mergers, changes of name, licenses, or releases are recorded against this patent. Ownership remained with Hoffmann-La Roche Inc. until expiry (2022-02-26).

Because the Assignment Center shows only the original chain (inventors → parent → US subsidiary) and no post-issuance assignments, the ownership analysis terminates here.

Timeline diagram

timeline
    title Ownership of US 6719996
    2001 : Kuentz and Roethlisberger assign to Roche AG
         : Roche AG assigns to Hoffmann La Roche Inc
    2002 : Both assignments recorded at USPTO
    2004 : Patent issues to Hoffmann La Roche Inc
    2022 : Patent expires with no further transfers

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. No assignee bears an "IP / Patents / Licensing / Holdings / Ventures" suffix; both assignees are named Roche operating entities. No LLC, no registered-agent address, no single-purpose entity appears in reel 012639/0256 or 012639/0267.

2. Known asserter in the chain — Not present. Neither assignee (F. Hoffmann-La Roche AG; Hoffmann-La Roche Inc.) matches any public NPE list (Acacia, Marathon, IV, Wi-LAN/Conversant, Pendrell, etc.). No NPE appears anywhere in the chain.

3. Repeat correspondent across the chain — Unclear / not assessable. The correspondent-of-record field for reel 012639/0256 and 012639/0267 could not be retrieved. I will not infer a repeat correspondent from the shared reel number alone. No NPE assertion list ties any attorney to this patent in the sources reviewed.

4. Cascading transfers — Not present. Only two assignments exist, executed one day apart, within the same corporate family. There is no chained-LLC sequence.

5. Pre-litigation transfer — Not present. The only assignments are dated 2001-11-21/22, i.e. before the patent existed and ~21 years before any litigation touching it. Nothing was recorded within 6 months of any suit. (The patent appears in the Helsinn v. Gland Pharma exhibit table of 2022 as a cited document; that is not an assignment-driven assertion signal, and I found no suit in which 6,719,996 is a patent-in-suit.)

6. Bankruptcy fire-sale — Not present. No Chapter 7/11, no sale order, no assignment out of an estate. Roche has no bankruptcy event covering this patent.

7. Privateering — Not present on the assignment record. Roche licensed the NK-1 chemistry (not this SELM patent) to Helsinn, which commercializes Akynzeo. That is a conventional out-license of a different asset; no NPE was set up to assert this patent against Roche's competitors.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN.

Verdict

Insufficient data — the recorded chain consists only of the original assignments (reel 012639/0267 executed 2001-11-21; reel 012639/0256 executed 2001-11-22), and ownership remained with Hoffmann-La Roche Inc. through expiry on 2022-02-26, with no post-issuance recordings. There are zero NPE indicators: no shell-entity transfer, no known asserter, no cascading LLCs, no pre-litigation transfer, and no defensive-aggregator endpoint. The honest read is a plain operating-company portfolio patent that was never assigned again and never asserted — not an NPE chain.

Verify against the USPTO record at https://assignmentcenter.uspto.gov/ (search "6719996"; the two reel 012639 entries should be the only hits). Note that the correspondent-of-record fields for those two entries should be pulled from the Assignment Center directly, since that field — the key tell for repeat-player attorney analysis — was not exposed in the sources available to this report.

I'll research US patent 6719996 and its cited prior art across the USPTO and related databases.

Let me research the two non-patent literature references cited on the face of the patent.

Prior-Art Analysis — US 6,719,996 B2

"Galenic composition for low bioavailability medicaments"

0. The patent under review (for reference, not repeated in full)

Critical claim-framing point for a §102 analysis: Every one of the 27 claims carries the two "point-of-novelty" limitations of the granted patent:

• Independent claim 1 requires, in addition to the quantitative limits (0.01–15% w/w active molecularly dissolved; 30–80% w/w edible lipid matrix; 1–20% w/w edible emulsifier; dose-weight/solubility ratio ≥ 0.6 ml), that the composition "comprises a chewable unit dosage form resembling a piece of chocolate."
• Independent claim 27 (process) likewise recites "a pharmaceutical composition comprising a chewable unit dosage form resembling a piece of chocolate."
• Claims 2–26 all depend (directly or ultimately) from claim 1 and therefore incorporate that limitation (35 U.S.C. § 112 ¶ 4).

Legal consequence: for a valid § 102 anticipation rejection, a single reference must disclose each element, including the chewable chocolate-resembling dosage form and the ≥ 0.6 ml ratio. A reference disclosing only the lipid/emulsifier/active matrix is, at best, a § 103 reference — not an anticipating one. This framing drives the conclusions below.

1. WO 1997/036577 A1 — Pharmos Corporation (applicant-cited)

Full citation: WO 1997/036577 A1, "Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability," Pharmos Corporation.
Dates: International filing/priority 1996-04-02; published 1997-10-09. (Google Patents: https://patents.google.com/patent/WO1997036577A1/en)
§ 102 category: Printed publication more than one year before the 2001-12-10 filing → § 102(b) art (also § 102(a) if before invention).

Brief description: Discloses solid lipid carrier compositions for delivering lipophilic, poorly water-soluble, poor-bioavailability compounds (the focus is coenzyme Q10, "practically insoluble in water," whose "oral bioavailability ... [is] generally very low"). The compositions combine a lipid/fat matrix with emulsifying/surfactant components to raise oral bioavailability — i.e., the same technical problem US 6,719,996 addresses.

Element mapping vs. claim 1:

Potential § 102 anticipation: None as issued. It shares the conceptual core of claim 1 (lipid + emulsifier to boost bioavailability of a low-bioavailability drug) but does not disclose the ≥ 0.6 ml solubility-volume ratio or the chewable chocolate-resembling dosage form. Most relevant to claims 1, 5, 6, 7, 8 and 13 as a § 103 reference (e.g., combined with US 6,375,982).

2. EP 1 035 115 A1 — F. Hoffmann-La Roche AG (applicant-cited)

Full citation: EP 1 035 115 A1, "4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists," F. Hoffmann-La Roche AG (Boes et al.).
Dates: Filed 2000-02-15; priorities 1999-02-24 (EP 99103504) and 1999-11-29 (EP 99123689); published 2000-09-13. (https://patents.google.com/patent/EP1035115A1/en)
§ 102 category: Printed publication before the priority/invention date → § 102(a).

Brief description: The drug-substance reference. It discloses the 4-phenylpyridine NK‑1 antagonist genus and, specifically, the three compounds named in claim 15 of US 6,719,996 (including 2‑(3,5‑bis‑trifluoromethyl‑phenyl)‑N‑methyl‑N‑(6‑morpholin‑4‑yl‑4‑o‑tolyl‑pyridin‑3‑yl)‑isobutyramide — the compound used in all Examples 1–5). US 6,719,996 itself concedes: "The above three compounds, whose synthesis may be found in EP‑A‑1035115, are characterized by valuable therapeutic properties."

Element mapping vs. claim 1: Discloses only the active compound; discloses no lipid matrix, no emulsifier, no molecular-dissolution requirement, no ≥ 0.6 ml ratio, and no chewable chocolate dosage form.

Potential § 102 anticipation: No claim is anticipated. This reference establishes that the claimed actives are known per se and that their low bioavailability is an inherent property — it is a § 102 reference for the compounds, not for the claimed compositions, and is why the patent claims a composition/process, not the molecules. Its practical role is evidentiary (anticipation the drug is old) and support for the "≤ 20% bioavailability" characterization. Relevant to claims 13–15 and 27 only as background.

3. US 6,375,982 B1 — Capricorn Pharma, Inc. (Cherukuri) (examiner-cited — the closest art)

Full citation: US 6,375,982 B1, "Rapid-melt semi-solid compositions, methods of making same and method of using same," Cherukuri, S. R.; Capricorn Pharma, Inc.
Dates: Filed 2000-07-05; granted 2002-04-23. (https://patents.google.com/patent/[US6375982B1](/patent/US6375982B1)/en). Related CIPs: US 6,589,556 B2; US 7,229,641 B2.
§ 102 category: Its 2000-07-05 filing predates the 2000-12-14 priority → available as § 102(e) prior art (a US patent granted on an application filed before applicant's invention). This is the only examiner-cited reference on the face of the patent.

Brief description: A rapid-melt, semi-solid molded composition comprising (a) a binder — preferably a lipid such as cocoa butter, hydrogenated vegetable oil, etc., 0.01–70% w/w; (b) a salivating agent, expressly including an emulsifier such as lecithin, 0.05–15% w/w; (c) a diluent/bulking material 10–90%; and (d) active material 0.001–70% w/w, prepared in the absence of free water. The product melts in the mouth (without chewing) and is molded/confectionary in form. Examples use cocoa butter + lecithin + sorbitan monostearate with calcium carbonate or (micro-encapsulated) acetaminophen. Its background expressly discusses GB 2 195 891/892 chocolate-type chewable tablet art.

Element mapping vs. claim 1:

Potential § 102 anticipation: No claim is anticipated as issued. US 6,375,982 is nonetheless the single most relevant prior art reference and the closest to the "chocolate‑like molded lipid/lecithin unit dose" element. Because it (i) teaches away from "chewable" (its product melts without chewing) and (ii) lacks the ≤ 20% bioavailability, molecular-dissolution, and ≥ 0.6 ml limitations, it is a § 103 reference against claims 1–9 and 27, not an anticipating one.

4. Aungst, B. J., et al. — International Journal of Pharmaceutics (1997) (applicant-cited, NPL)

Full citation: Aungst, B. J.; Nguyen, N. H.; Rogers, N. J.; Rowe, S. M.; Hussain, M. A.; White, S. J.; Shum, L., "Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses," International Journal of Pharmaceutics, Vol. 156, No. 1, pp. 79–88 (1997).
Date: 1997 (more than one year before the 2001-12-10 filing). § 102(b) printed publication.
Brief description: Reports that a poorly water-soluble drug (DMP 323) loses bioavailability at high dose because of GI precipitation, and that amphiphilic/lipid vehicles (Gelucire 44/14, a glyceride/PEG-ester mixture) restore ~50% bioavailability at high dose; explicitly identifies that a limitation of the approach is the volume of vehicle required. This is directly the rationale underlying US 6,719,996's ≥ 0.6 ml "volume available for molecular dispersion" parameter. (Verified via bibliographic catalog: Università di Bologna Spogli record.)

Potential § 102 anticipation: None. It is a journal study of a different drug/vehicle and discloses no lipid-matrix + emulsifier formulation with the claimed ranges, ratio, or dosage form. § 103 background art supporting the motivation to use large-volume amphiphilic/lipid vehicles.

5. Serajuddin, A. T. M., et al. — Journal of Pharmaceutical Sciences (1999) (applicant-cited, NPL)

Full citation: Serajuddin, et al., Journal of Pharmaceutical Sciences (American Pharmaceutical Association, Washington, US), Vol. 88, No. 10, pp. 1058–1066 (1999). (Caveat: the exact article title is not reproduced on the patent face; this is the Serajuddin JPS 1999;88(10):1058–66 paper on amphiphilicity/solubilization and bioavailability of poorly water-soluble drugs. Title should be verified against the source before being quoted in any filing.)
Date: 1999 — more than one year before the 2001-12-10 filing → § 102(b).
Brief description: Discusses how vehicle amphiphilicity governs dissolution and oral bioavailability of poorly water-soluble drugs (solubilization/pH-partitioning concepts). Background literature for the "poorly soluble, low-bioavailability drug needs an amphiphilic vehicle" problem statement.

Potential § 102 anticipation: None. It is not directed to a lipid-matrix/emulsifier chewable dosage form and discloses none of the claim-1 quantitative or structural limitations. § 103 background only.

6. References that are not prior art (avoid misciting)

The page's "Cited By," "Families Citing this family," and "Similar Documents" lists are later documents and are not available as prior art against US 6,719,996, e.g.: SE 0200475 (LTP Lipid Technologies, 2002-02-15); SE 0201922 (2002-06-20); MX PA/a/2007/000198 (Roche, from a 2004 application); NZ 560232 (2005); CN 107404893; CN 109200018; Karavasili et al., 2020; and the Helsinn netupitant/palonosetron family (2009+). Also same-family members (not separate art): CA 2,431,397 C and AU 2002216085 ("Self Emulsifying Lipid Matrix (SELM)"), WO 2002/047663 A1, EP 1 349 541 B1.

7. Bottom line

No cited reference, taken alone, discloses every element of claim 1 (most importantly the "chewable unit dosage form resembling a piece of chocolate" and the ≥ 0.6 ml dose-weight/solubility ratio). The most relevant prior art is (i) US 6,375,982 B1 — closest on the molded cocoa-butter/lecithin confection form (examiner-cited) — and (ii) WO 1997/036577 A1 — closest on the lipid-matrix/emulsifier-for-low-bioavailability-drug concept. Any challenge to the granted claims would therefore have had to run through § 103 (e.g., US 6,375,982 in view of WO 1997/036577 and/or EP 1 035 115), not § 102 — which is consistent with the granted claim set retaining the chocolate-resembling chewable-form limitation that the pre-grant publication (US 2002/0114837 A1) did not carry into allowance.

Confidence caveats: (1) Dates/identifiers above are taken literally from the patent's own citation tables and Google Patents/PubChem and were not re-verified against the USPTO PatentCenter register. (2) The Serajuddin NPL title is not printed on the patent face and should be verified. (3) Per the operating rule, if live USPTO records conflict with this analysis, the records govern.

I'll ground each prior-art reference from the patent's Prior Art section before building the § 103 analysis.

Now the two non-patent citations and the SEDDS review.

Obviousness Analysis — U.S. Patent No. 6,719,996 B2 under 35 U.S.C. § 103

Scope note. This is a defensive/analytical obviousness assessment, not a litigation position. It builds on the two prior sections (patent summary; litigation summary) and does not repeat their bibliographic or family content. The applicant's application was filed 2001-12-10 with a 2000-12-14 EP priority date, so the pre-AIA § 102/§ 103 framework applies (no first-inventor-to-file grace-period analysis).

0. What the "Prior Art section" of the page actually supplies

Two clarifications before analysis, so nothing is mis-attributed:

• The page's "Prior art keywords" (pharmaceutical composition; composition according; active compound; emulsifier; solubility) are machine-generated keyword tags, not references. They carry no evidentiary weight.
• The citable prior art on the page is: Citations (3) — WO1997036577A1; EP1035115A1; US6375982B1 — plus Non-Patent Citations (2) — Aungst et al., Int. J. Pharm. 156(1):79–88 (1997); Serajuddin et al., J. Pharm. Sci. 88(10):1058–1066 (1999). A third body of art is applicant-admitted in the specification itself: C. W. Pouton, Adv. Drug Delivery Rev. 25:47–58 (1997), and A. Martin, Physical Pharmacy, 4th ed., Lea Febiger, 1993, 221–237 (cited to establish that dissolution of solid actives in polar/apolar media is routine and calculable).

Prior-art dates (verified): WO 97/36577 published 1997-10-09 (US counterpart US 5,989,583, Pharmos); EP 1,035,115 A1 published 2000-09-13 (priority 1999-02-24); US 6,375,982 B1 issued 2002-04-23 on an application filed 2000-07-05 (Capricorn Pharma), i.e. before the '996 priority date, making it prior art under pre-AIA § 102(e). Aungst 1997 and Serajuddin 1999 are printed publications under § 102(a)/(b).

1. The hypothetical person of ordinary skill in the art (PHOSITA)

A formulator with an advanced degree (M.S./Pharm.D./Ph.D.) or 3–5 years' experience in oral lipid-based drug delivery, familiar with (i) self-emulsifying/microemulsifying systems (SEDDS/SMEDDS) as of 1997–2000, (ii) GRAS lipid and emulsifier excipients (cocoa butter, vegetable triglycerides, lecithins, polysorbates, polyglycolized glycerides), (iii) preformulation solubility screening and dose:solubility ("theoretical loading") calculations, and (iv) pediatric/geriatric dosage-form design (chewables, melt-in-mouth matrices).

2. Scope and content of each reference

A. WO 97/36577 (Pharmos) — Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability. Its stated premise is that "Lipophilic substances possessing low water solubility often have poor oral bioavailability" and that even oil solutions/emulsions leave bioavailability "still very low." It claims solid lipid compositions comprising at least one solid fat (a lipid matrix) plus other excipients, and expressly teaches (claims 11/15) adding a synthetic surface-active material or an emulsifier to the dispersion. The '996 specification itself acknowledges this reference ("WO 97/36577 discloses dry solid mixtures in which a drug is poorly stabilized," per the EP 1 349 541 counterpart background) — a stability criticism, not a technical disavowal of the claimed architecture.

B. EP 1,035,115 A1 (F. Hoffmann-La Roche) — 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists. This is the drug source: the '996 specification states the three named compounds' "synthesis maybe [sic] be found in EP-A-1035115," and the three species of claim 15 are Roche's 4-phenylpyridine NK-1 antagonists (including 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide). It discloses the compounds, their NK-1 affinity, and their therapeutic utility — not any formulation. Its relevance is that it supplies the claimed active species and the physicochemical profile (highly lipophilic, bis-CF₃ aryl + o-tolyl) that predicts poor aqueous solubility.

C. US 6,375,982 B1 (Capricorn Pharma / Cherukuri) — Rapid-melt semi-solid compositions. This is the closest reference on the dosage form element. Its own words: "semi-solid product formulations containing one or more certain lipid materials, emulsifiers and particulate materials are highly palatable and effective compositions for the delivery of pharmaceutical active materials," with the object of serving "the fields of pediatric and geriatric care." Claim 1 claims a molded composition of binder 0.01–70% w/w + salivating agent 0.05–15% + diluent/bulking 10–90% + active 0.001–70%; claim 2 specifies the binder is a lipid material melting at 25–90 °C; claim 3 a lipid melting near 37 °C. Example #17 is a cocoa-butter molded chewable: 19.00 g cocoa butter, 0.34 g lecithin, 1.00 g sorbitan monostearate, PEG, aspartame, sugar 10×, strawberry and vanilla flavorings, molded and set. Compositions "melt without any chewing" or upon "a slight amount of chewing." (Provenance note: the later ex parte reexamination certificate US 6,375,982 C1, reexam 90/010,441, concerns Capricorn's patent — not US 6,719,996, and is not litigation; it does not disturb the earlier litigation finding.)

D. Aungst et al. 1997 — Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Teaches that lipid + amphiphile (surfactant/emulsifier) vehicles raise oral bioavailability of a poorly soluble drug, expressly "at high doses" — i.e., it addresses the drug-load axis directly.

E. Serajuddin 1999 — Solid dispersion of poorly water-soluble drugs. Teaches use of "surface-active and self-emulsifying carriers" and direct melt-encapsulation into hard gelatin capsules to form solid plugs, obtaining "complete dissolution of drug from such solid dispersions." Critically for the ratio limitation, it identifies the failure mode: "Some practical limitations of dosage form development might be the inadequate solubility of drugs in carriers…" — the art knew the vehicle-volume/solubility ceiling.

F. Applicant-admitted art (in the '996 specification). Pouton 1997 (SEDDS improve bioavailability and give "a more consistent temporal profile of absorption"); Martin, Physical Pharmacy (measuring drug solubility in polar/apolar media).

3. Claim 1 element-by-element mapping

No single reference discloses every element — so the correct ground is a § 103 combination, not § 102.

4. Combinations that render claim 1 obvious

Primary combination: Capricorn (US 6,375,982) + Pharmos (WO 97/36577) + EP 1,035,115 A1, further in view of Aungst 1997 and Serajuddin 1999

Claim 1 is the sum of (i) a molded, chewable, chocolate-like lipid base, (ii) a self-emulsifying lipid/emulsifier matrix holding a high drug load in solution, and (iii) a specific lipophilic active. Each is taught by one of the references, and each combination is a KSR/MPEP 2143 (A) "known elements combined according to known methods to yield predictable results" case:

1. Capricorn supplies the structural core. It teaches the molded, no-free-water, cocoa-butter/lecithin, sweetened/flavored, chewable semi-solid that is the claimed "chewable unit dosage form resembling a piece of chocolate," with binder (lipid matrix) up to 70% w/w, and it supplies the express motivation — palatability and pediatric/geriatric compliance — the same rationale the '996 specification invokes ("the positive result of a therapy depends on patient compliance").
2. Pharmos supplies the functional upgrade from a mere confection matrix to a self-emulsifying lipid matrix. WO 97/36577 addresses exactly the problem in claim 1's preamble (poor oral bioavailability of lipophilic drugs) and expressly teaches adding an emulsifier to the lipid carrier. A PHOSITA would add that emulsifier to the Capricorn cocoa-butter matrix for the reason Pharmos states — improving bioavailability — with no change in the manufacturing technique (melt, mix, mold).
3. EP 1,035,115 supplies the active. Reason to select it: it is Roche's own compound class with known NK-1 therapeutic utility and obvious GI-administration need, and its highly lipophilic structure predicts the very solubility problem the lipid vehicle solves. Selecting a known compound for a known use in a known vehicle is routine (KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007)).
4. Aungst 1997 and Serajuddin 1999 close the "high drug load" gap and the ratio limitation. Aungst teaches that amphiphilic vehicles improve bioavailability of a poorly soluble drug at high doses; Serajuddin teaches melt-in-carrier solid solutions and, decisively, articulates the "inadequate solubility of drugs in carriers" limitation of the capsule-bound art. Recognizing that the vehicle volume must be at least dose ÷ solubility is not an inventive insight — it is the arithmetic of the applicant's own admitted reference (Martin, Physical Pharmacy) applied to a limitation the art had already identified. Reciting a calculated parameter does not patentably distinguish the prior art where the underlying physical difference is not shown to be significant: In re Swinehart, 439 F.2d 210 (CCPA 1971) (newly discovered property inherent in the prior art); In re Woodruff, 919 F.2d 1575 (Fed. Cir. 1990) (recited parameter must reflect a real difference).

Secondary combination: Capricorn + Serajuddin alone (drug-generic claims)

For a claim not limited to a specific active, Capricorn (molded cocoa-butter/lecithin chewable, lipid binder to 70%, active to 70%) + Serajuddin (self-emulsifying carriers; melt-filled solid dispersions; drug in true solution; acknowledged carrier-solubility ceiling) renders claim 1 obvious. The only arguable gap — a lipid matrix at 30–80% w/w rather than Capricorn's ~19–22% in Example #17 — is closed by WO 97/36577 (lipid as the matrix) and by routine optimization: adjusting a batch percentage within a disclosed range (Capricorn's binder up to 70%) is obvious optimization in the absence of criticality (In re Aller, 220 F.2d 454 (CCPA 1955); MPEP 2144.03).

5. Motivations to combine (reasoned articulation)

No teaching away. Under In re Fulton and Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir. 2006), a reference must criticize, discredit, or discourage the claimed solution. WO 97/36577's "dry solid… poorly stabilized" criticism targets a dry-powder format, not a high-lipid melt; merely providing an alternative is not teaching away. The art likewise did not disparage high-lipid chewables — Capricorn actively endorsed them.

6. Dependent claims (2–26) — separately obvious

• Claims 2, 16 (lipid 50–75%): obvious optimization of claim 1's 30–80%, and within Capricorn's binder range (to 70%). Internal-evidence note: the '996 Examples mostly sit at 70.08–77.08% cocoa butter, so Example 3 (77.08% cocoa butter) falls outside claim 2/16 — evidence the 50–75% sub-range carries no demonstrated criticality beyond claim 1.
• Claims 3–4, 17–18 (emulsifier 1–10%, then 2–8%): routine narrowing; '996 Ex. 1–4 span 1–8% w/w.
• Claims 5–6, 19–20 (vegetable triglycerides; cocoa butter): Capricorn Example #17 literally uses cocoa butter; WO 97/36577 uses solid vegetable fats.
• Claims 7–8, 21–22 (lecithins / polyglycolized triglycerides; soya lecithin): Capricorn Example #17 uses lecithin; its polyoxyethylene sorbitan ester (Polysorbate) and polyglycerol ester map onto the '996 specification's Polysorbates 20/40/65/80/85 and polyglycolized glycerides (Cremophor EL/RH).
• Claims 9, 23 (sweeteners/flavors): Capricorn literally uses aspartame, sugar 10×, vanilla and strawberry flavoring.
• Claims 10–12, 24–26 (ratio ≥1.2 mL; 1.2–10 mL; 3–7 mL): pure optimization of a calculated dosing parameter; the sole asserted consequence (bioavailability) is a continuum (Table 1 spans 4%–68%), and the claim covers the poor end of it (Ex. 1: 7% and 4% in fasted dogs) — evidence the parameter lacks criticality. Under In re Grasselli, 713 F.2d 731 (Fed. Cir. 1983), asserted unexpected results must be commensurate with the claim scope.
• Claims 13–15, and 16–26 (drug classes, 4-phenylpyridines, the three named species): EP 1,035,115 A1 discloses the compounds and the class; the '996 specification concedes the compounds are known from EP-A-1035115. Claiming a known compound in a known, improved vehicle is the paradigm KSR case.

7. Where an obviousness challenge is weakest (foreseeable rebuttals)

1. "Molecularly dissolved" is a functional limitation. Capricorn's own examples use coated microcaps (e.g., "coated acetaminophen microcaps," "coated ibuprofen microcaps"), i.e., suspended, not dissolved, drug. A Capricorn-only theory therefore does not literally meet this element; the combination must rely on Serajuddin's molecular solid dispersions or on WO 97/36577's lipid solutions.
2. No single reference teaches the 0.6 mL ratio. The ratio limitation is the strongest non-obviousness hook because it is framed as a newly appreciated parameter. Rebut the Swinehart/Woodruff way: the parameter quantifies an inherent physical fact (vehicle volume ≥ dose ÷ solubility) that Serajuddin and Aungst had already flagged qualitatively, and no difference in kind is shown.
3. Secondary considerations. Applicant would emphasize the Table 1 superiority (up to 68% SELM vs. 13–27% for the Example 5 SEDDS vs. 0.6–7% for crystalline capsules). Weaknesses: (a) the comparative SEDDS used a different, smaller vehicle volume (capsule-bound; ≤20 mg drug), so it is not a controlled comparison of the claimed feature; (b) results are highly variable (same Example 1: 7% vs 4% fasted, 17% vs 22% fed) and the Examples do not isolate the ratio variable; (c) any nexus to the chewable chocolate limitation — the added-on element — is unsupported.
4. § 103(c) (pre-AIA) caveat. Subject matter qualifying as prior art only under § 102(e)/(f)/(g) and commonly owned is disqualified under § 103. This could matter for Roche-vs-Roche art, but not for US 6,375,982, which is Capricorn's (third-party) and therefore fully available. EP 1,035,115 A1, being a printed publication, is § 102(a) art and outside the § 103(c) safe harbor regardless.
5. Prosecution-history inference, flagged as inference. The earlier section inferred that the "chewable unit dosage form resembling a piece of chocolate" element was added at grant to secure allowance. I have not reviewed the file wrapper, so I cannot confirm the examiner's stated reason. If allowance turned on that element while US 6,375,982 was of record and discloses a molded cocoa-butter/lecithin chewable semi-solid, the allowance rationale is questionable on its face — which strengthens, not weakens, the § 103 attack.

8. Internal inconsistencies I flag rather than auto-correct

1. Ratio lower bound conflict. The Summary states the ratio is "favorably equal to or greater than 1.2 ml, more favorably between about 1.2 ml and about 10 ml," but the Detailed Description immediately says "equal to or greater than 1.2 ml, more preferably it varies between 0.6 and 10 ml." Claims 10/11 and 24/25 use 1.2 mL; claim 1/27 use 0.6 mL. This affects the § 103 "optimization" analysis of claims 10–12 (a 0.6–10 mL embodiment is disclosed but unclaimed).
2. Claim 2/16 vs. Example 3. Example 3 (77.08% cocoa butter) exceeds the 50–75% w/w range of claims 2 and 16.
3. "SEEDS"/"SEDDS" spelling. Preserved literally per the earlier section; not normalized.
4. Date variance. This task header states the current date as 2026-04-26; the authoritative patent text supplied to me was fetched 2026-09-30. I have not attempted to reconcile these and have treated the patent text as controlling.

9. Bottom line

• Claim 1 is, on this record, vulnerable to § 103 over US 6,375,982 (Capricorn) in view of WO 97/36577 (Pharmos) and EP 1,035,115 A1, with Aungst 1997, Serajuddin 1999, and the applicant-admitted Pouton 1997 / Martin references supplying the high-dose rationale and the dose:solubility parameter. The single most attackable element is the calculated ≥0.6 mL ratio (an inherent, art-recognized physical fact) and the aesthetic "resembling a piece of chocolate" language (little or no patentable weight, and squarely taught by Capricorn).
• Claim 27 falls with claim 1: the process steps (select drug/lipid/emulsifier; mix in the stated proportions) are the routine melt-mix-mold sequence taught by Capricorn, WO 97/36577, and Serajuddin.
• Dependent claims 2–26 are obvious as optimizations of disclosed ranges and selections of disclosed species (lecithin, cocoa butter, Polysorbates, aspartame, vanillin — all in Capricorn; the three actives — in EP 1,035,115 A1), with no demonstrated criticality for the narrower ranges (Examples 1–4 straddle several of them).
• Confidence: Moderate-to-high on the combinations and motivation; lower on the ultimate merits, because I have not reviewed the US 10/015,925 file wrapper, any Rule 132 declarations, or the exact reasons for allowance. A robust conclusion would require the office actions and any § 1.132 evidence of record.